Trade and buy Alert, Bought $CORT at $2.00, target opinion per chart = $2.50 short term. Pinched chart making a bounce back, minimal resistance til $2.50
Athersys: Upcoming Short Term Catalyst With Promising Longer Term Potential
In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, I wrote about Pluristem Therapeutics (PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products…
CORRECTED CHARTS: Chart and commentary on $ATHX and others + Trading Technicals
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. Honoring Dr. King by following his example of looking at a…
Charts and commentary on $ATHX and others + Trading analysis. Honor Dr. King today.
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers commentary. YouTube Video, enjoy!
Neptune’s Bounce Should Continue: $3 in range
Originally posted at www.biomedreports.com Updated by StockMatusow.com Twitter @BioMedReports @ScottMatusow Neptune Technologies & Bioressources announced they will hold a conference call on Thursday, January 17th at 4:30 EST. The reason given for the call will be to discuss the third…
Clarification from BioLineRX (BLRX) on March 18th Data release
I have received the following letter from the company in regards to its week of March 18th data release on its schizophrenia drug in Phase II/III. “Dear Scott, Thank you for approaching us with your clarification questions. The independent Data…
BioLineRx: Big Catalyst Upcoming With Potential Multi Billion Dollar Schizophrenia Drug
BioLineRx’s (BLRX) engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in…
Legendary Icahn Still Slugging Away With Enzon Pharma
Carl C. Icahn has been the principal beneficial shareholder of Icahn Enterprises L.P. (NYSE: IEP) and has served as Chairman of the board, a director, and an owner of the company’s general partner since 1990. Mr. Icahn heads the investment…
